查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1997199

癌症切片檢查市場：按產品類型、技術、應用和最終用戶分類－2026-2032年全球市場預測

Cancer Biopsy Market by Product Type, Technology, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症切片檢查市場價值將達到 377.6 億美元，到 2026 年將成長至 425.9 億美元，到 2032 年將達到 887.2 億美元，複合年成長率為 12.98%。

主要市場統計數據
基準年 2025 377.6億美元
預計年份：2026年 425.9億美元
預測年份：2032年 887.2億美元
複合年成長率 (%) 12.98%

一個策略框架，用於了解臨床需求、醫療設備創新和醫療保健服務體系重組如何共同塑造所有醫療保健機構中的現代癌症切片檢查實踐。

引言部分將現代癌症切片檢查實踐置於臨床需求、技術創新和不斷發展的醫療服務模式的交匯點。影像學、設備和操作引導技術的進步正在改變診斷流程，而人們對準確性、患者舒適度和結果獲取速度的日益成長的期望，凸顯了微創切片檢查技術的重要性。因此，多學科團隊正在修訂通訊協定，以平衡診斷準確性、處理能力和成本，而管理者則優先考慮符合更廣泛醫療目標的活體組織切片方法。

關鍵的變革揭示了影像技術的進步、向門診護理的轉變以及跨學科工作流程如何重新定義切片檢查實踐。

切片檢查領域正經歷著一場變革，其驅動力包括技術的成熟、工作流程的重新設計以及對以患者為中心的治療效果日益重視。影像導引技術日趨成熟，能夠更精準地標靶化病灶並減少無法偵測的樣本。同時，一些醫療機構開始採用機器人和自動化技術來提高營運的可重複性和安全性。此外，隨著臨床醫生和管理人員尋求降低成本、提高處理能力和改善患者體驗，活體組織切片流程正從住院部轉向門診手術中心和影像中心。

2025 年的關稅環境將如何改變癌症切片檢查中使用的醫療設備和耗材的籌資策略、採購韌性和服務交付成本模式？

2025年近期一系列關稅措施的累積影響，將進一步加劇依賴跨境供應鏈採購切片穿刺針、影像設備、一次性用品及配件的採購團隊、製造商和臨床醫生的困境。部分醫療設備及組件進口關稅的提高推高了整體成本，促使企業重新評估籌資策略。在此背景下，採購經理被敦促優先考慮供應商多元化、盡可能選擇近岸外包，以及建立能夠分散整個供應鏈風險的合約結構。

細分市場主導的洞察揭示了產品、應用、技術和最終用戶方面的差異如何影響臨床選擇、採購和創新重點。

精細化的細分觀點能夠清楚地展現臨床需求、技術適用性和終端使用者能力之間的交集，從而揭示決定部署模式和操作優先順序的關鍵因素。產品類型差異化突顯了不同選項（例如粗針穿刺活體組織切片和細針真空輔助切片檢查）之間的性能權衡，以及切片檢查活體組織切片和真空輔助切片檢查在不同臨床場景中的相對作用。這些技術在檢體量、診斷率和手術環境要求方面存在差異。基於應用的細分方法則突顯了每個腫瘤部位的特定臨床途徑和檢體處理要求。這包括乳腺癌、肝癌、肺癌、前列腺癌和甲狀腺癌手術中獨特的流程，從而影響儀器選擇和影像需求。

區域趨勢和各大區域醫療服務差異會影響設備部署、監管策略和臨床工作流程的最佳化。

區域趨勢在塑造臨床通訊協定、報銷框架和設備可用性方面發揮決定性作用，進而影響著技術的普及曲線和供應商策略。在美洲，醫療保健系統是公私部門複雜混合體，成本控制和以價值為導向的醫療結果備受重視，醫療服務提供者往往傾向於選擇處理效率高、診斷準確可靠的醫療程序。該地區的監管管道和報銷政策也促進了微創技術的應用，這些技術能夠縮短住院時間並加快診斷速度。

競爭考察和策略業務洞察，重點關注設備整合、證據產生和夥伴關係主導的診斷管道的創新。

切片檢查系統的競爭動態是技術差異化、策略夥伴關係和聚焦臨床證據建構三者相互交織的結果。主要企業正優先投資於整合式操作平台，這些平台具備影像相容性、檢體保存技術，能夠簡化臨床醫師的工作流程，並降低非診斷率。透過同儕審查研究和真實世界數據證明其能夠改善臨床療效的企業，正在贏得關鍵意見領袖 (KOL) 和醫院採購委員會的信任，從而加速其技術在醫療機構中的應用。

為製造商、供應商和採購經理提供具體、高優先順序的策略建議，以改善結果、降低供應風險並加快部署。

醫療設備製造、醫院系統和診斷服務的領導者可以採取實際措施來提升臨床療效、業務永續營運和商業性績效。首先，應投資收集證據，證明其在診斷準確性、後續治療決策和患者報告結果方面的改進。這些數據將有助於採購談判和臨床醫生的認可。其次，應制定靈活的供應鏈和供應商多元化計劃，以降低單一來源供應中斷的風險，並透過認證替代零件和近岸供應商來應對關稅帶來的成本壓力。

透過結合對臨床醫生的訪談、對醫療設備的技術審查以及對證據的三角檢驗，我們採用嚴謹且多方面的調查方法，以確保獲得高度可靠和實用的見解。

本研究採用檢驗法，整合質性和量性證據，強調資料的完整性和可重複性。主要資料來源包括對臨床醫生、採購經理和器械工程師的結構化訪談，以了解手術流程偏好、器械性能權衡以及實施經驗。次要研究包括同行評審文獻、監管文件、手術指南和公開的技術規範，以檢驗臨床結論並為技術進步提供背景資訊。

對策略挑戰和營運重點進行簡潔整合，以決定哪些切片檢查方法將被廣泛採用並獲得臨床信任。

總之，分析得出的關鍵主題可概括如下：臨床需求、技術進步和操作限制正在推動活體組織切片解決方案朝向更精準、創傷更小、更符合工作流程的方向發展。醫療決策者必須權衡各種流程的有效性與操作方面的考量，例如處理能力、訓練負擔和供應鏈穩定性。隨著切片檢查流程與分子檢測的融合日益加深，檢體完整性和標準化處理通訊協定的重要性可能日益凸顯。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症切片檢查市場：依產品類型分類

  • 核心針穿刺切片
  • 細針真空輔助切片檢查
  • 手術切片檢查
  • 真空輔助切片檢查

第9章：癌症切片檢查市場：依技術分類

  • 影像引導切片檢查
  • 徒手切片檢查
  • 機器人輔助切片檢查

第10章 癌症切片檢查市場：依應用領域分類

  • 胸部
  • 肝
  • 肺
  • 攝護腺
  • 甲狀腺

第11章：癌症切片檢查市場：按最終用戶分類

  • 門診手術中心
  • 影像中心
  • 醫院
  • 診所

第12章 癌症切片檢查市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：癌症切片檢查市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癌症切片檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國癌症切片檢查市場

第16章：中國癌症切片檢查市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Argon Medical Devices, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Boston Scientific Corporation
  • Cardinal Health, Inc.
  • Danaher Corporation
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • QIAGEN NV
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-C27187914300

The Cancer Biopsy Market was valued at USD 37.76 billion in 2025 and is projected to grow to USD 42.59 billion in 2026, with a CAGR of 12.98%, reaching USD 88.72 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 37.76 billion
Estimated Year [2026] USD 42.59 billion
Forecast Year [2032] USD 88.72 billion
CAGR (%) 12.98%

A strategic framing of how clinical needs, device innovation, and care delivery reconfiguration are jointly shaping modern cancer biopsy practice across care settings

The introduction positions contemporary cancer biopsy practice at the confluence of clinical imperative, technological innovation, and evolving care delivery models. Advances in imaging, instrumentation, and procedural guidance have reshaped diagnostic workflows, while heightened expectations for precision, patient comfort, and turnaround time have elevated the role of minimally invasive sampling techniques. Consequently, multidisciplinary teams are recalibrating protocols to integrate diagnostic accuracy with throughput and cost considerations, and administrators are prioritizing modalities that align with broader value-based care objectives.

As stakeholders confront workforce constraints, regulatory scrutiny, and shifting payer dynamics, the case for robust evidence on procedure choice, technology adoption, and site-of-care optimization grows stronger. Therefore, this executive summary frames the critical trends influencing practice patterns, supply chains, and vendor strategies, offering readers a clear orientation to the underlying forces redefining how tissue acquisition is selected, performed, and managed across diverse clinical settings.

Key transformative shifts revealing how imaging advances, care migration to ambulatory settings, and interdisciplinary workflows are redefining biopsy practice

The landscape of cancer biopsy is undergoing transformative shifts driven by technological maturation, workflow redesign, and a heightened emphasis on patient-centered outcomes. Imaging-guided approaches have become more sophisticated, enabling more precise targeting of lesions and reducing non-diagnostic sampling, while robotics and automation are beginning to emerge in select centers to improve reproducibility and safety. Meanwhile, procedural pathways are migrating from inpatient settings to ambulatory surgical centers and diagnostic imaging centers as clinicians and administrators seek to lower costs, improve throughput, and enhance patient experience.

In parallel, there is a convergence of diagnostic modalities, with pathologists, radiologists, and interventionalists collaborating more closely to ensure that tissue sampling is optimized for downstream molecular and genomic testing. This interdisciplinary integration is influencing device design, specimen handling protocols, and supply chain arrangements. As a result, manufacturers and providers must adapt their strategies to support seamless care coordination, regulatory compliance, and quality assurance, all while addressing patient preferences and institutional efficiency mandates.

How the 2025 tariff environment is reshaping sourcing strategies, procurement resilience, and cost-to-serve models for devices and consumables used in cancer biopsy

The cumulative impact of recent tariff actions in 2025 introduces a layer of complexity for procurement teams, manufacturers, and clinical providers that rely on cross-border supply chains for biopsy needles, imaging hardware, disposables, and accessory devices. Increased import duties on select medical devices and components amplify landed costs and create incentives for firms to reassess sourcing strategies. This environment encourages procurement leaders to prioritize supplier diversification, nearshoring where feasible, and contract structures that allocate risk across the supply chain.

Operationally, hospitals and diagnostic centers face tighter budgetary constraints and may extend inventory pooling and consignment arrangements to mitigate price volatility. In response, device makers are exploring redesigns that substitute tariff-exposed components, negotiating long-term supply agreements, and accelerating qualification of alternative suppliers. Regulatory compliance and quality assurance remain non-negotiable, so any sourcing pivot must preserve clinical performance and sterility standards. Ultimately, the tariff environment is prompting a re-evaluation of cost-to-serve models, while underscoring the need for transparent supplier relationships and scenario planning to maintain clinical continuity.

Segment-driven insights revealing how product, application, technology, and end-user differences drive clinical choice, procurement, and innovation priorities

A granular segmentation lens clarifies where clinical demand, technology fit, and end-user capabilities intersect to determine adoption patterns and operational priorities. Product Type distinctions illuminate performance trade-offs between alternatives such as Core Needle Biopsy versus Fine Needle Aspiration, and the relative roles of Surgical Biopsy and Vacuum-Assisted Biopsy in different clinical scenarios; these modalities differ in sample volume, diagnostic yield, and procedural setting requirements. Application-based segmentation highlights unique clinical pathways and specimen handling demands across tumor sites, including distinct workflows for Breast, Liver, Lung, Prostate, and Thyroid procedures that influence device selection and imaging needs.

Technology segmentation underscores the implications of Imaging Guided Biopsy compared with Manual Freehand Biopsy and the emerging role of Robotic Assisted Biopsy in enhancing precision and reproducibility, while end-user segmentation reveals how operational capabilities vary across Ambulatory Surgical Centers, Diagnostic Imaging Centers, Hospitals, and Physicians Offices. When combined, these perspectives support targeted product development, differentiated training programs, and tailored commercial approaches that align device features with the clinical and operational realities of each segment.

Regional dynamics and care delivery variations across major geographies that influence device adoption, regulatory strategy, and clinical workflow optimization

Regional dynamics play a decisive role in shaping clinical protocols, reimbursement frameworks, and device availability, which in turn influence adoption curves and vendor strategies. In the Americas, healthcare systems span complex private and public mixes with strong emphasis on cost containment and value-based outcomes, prompting providers to favor procedures that deliver robust diagnostic yield with efficient throughput. Regulatory pathways and reimbursement policies in this region also incentivize adoption of minimally invasive techniques that reduce length of stay and expedite diagnosis.

Europe, Middle East & Africa present a heterogeneous landscape where national health systems and varying levels of infrastructure affect technology diffusion. In higher-resource markets, there is rapid uptake of advanced imaging-guided and robotic-assisted solutions, whereas other markets prioritize durable, cost-effective devices and local training to expand access. In Asia-Pacific, rapid urbanization, investments in oncology infrastructure, and high procedural volumes drive demand for scalable solutions and integrated diagnostic pathways. Across all regions, local regulatory requirements, supply chain considerations, and workforce skills shape the practical rollout of new biopsy technologies and service models.

Competitive and strategic company insights highlighting innovation in device integration, evidence generation, and partnership-driven diagnostic pathways

Competitive dynamics in the biopsy ecosystem reflect a blend of technological differentiation, strategic partnerships, and focused clinical evidence development. Leading firms are prioritizing investments in imaging compatibility, specimen preservation technologies, and integrated procedural platforms that streamline clinician workflows and reduce non-diagnostic rates. Companies that demonstrate clinical outcomes improvements through peer-reviewed studies and real-world evidence gain credibility with key opinion leaders and hospital procurement committees, thereby accelerating institutional adoption.

At the same time, smaller, specialized entrants are carving niches by addressing unmet procedural needs, such as biopsy devices tailored for difficult-to-access lesions or tools optimized for molecular-grade specimen collection. Strategic collaborations between device makers and pathology or genomic testing providers are emerging to ensure that the entire diagnostic pathway, from tissue acquisition to molecular analysis, is optimized. Finally, commercial strategy is increasingly informed by service models-training, procedural support, and bundled offerings-that help providers adopt new technologies with lower operational friction.

Practical and prioritized strategic recommendations for manufacturers, providers, and procurement leaders to improve outcomes, mitigate supply risk, and accelerate adoption

Leaders in device manufacturing, hospital systems, and diagnostic services can take concrete steps to strengthen clinical outcomes, operational resilience, and commercial performance. First, invest in evidence generation that demonstrates improvements in diagnostic yield, downstream treatment decision-making, and patient-reported outcomes; such data supports procurement discussions and clinician acceptance. Second, develop flexible supply arrangements and supplier diversification plans that reduce exposure to single-source disruptions and respond to tariff-driven cost pressures by qualifying alternative components and nearshore suppliers.

Third, align product development with the nuanced needs of each clinical application and end user by incorporating feedback from interventional radiology, pathology, and oncology teams; tailoring training and onboarding reduces implementation risk. Fourth, pursue strategic partnerships that integrate tissue acquisition with downstream molecular testing to create end-to-end solutions valued by health systems. Finally, prioritize digital enablement-data capture, workflow integration, and remote proctoring-to improve quality assurance and facilitate scale across disparate sites of care.

A rigorous, multi-source research methodology combining clinician interviews, device technical review, and evidence triangulation to ensure credible and actionable insights

The study synthesizes qualitative and quantitative evidence using a triangulated research approach that emphasizes data integrity and reproducibility. Primary inputs include structured interviews with clinicians, procurement leaders, and device engineers to capture procedural preferences, device performance trade-offs, and implementation experience. Secondary research encompasses peer-reviewed literature, regulatory filings, procedural guidelines, and publicly available technical specifications to validate clinical claims and contextualize technological advances.

Analytical rigor is achieved through methodical cross-validation across data streams, sensitivity checks on key assumptions, and iterative review by clinical experts to ensure that interpretations reflect frontline practice. Where applicable, case studies and vendor-provided clinical data are assessed for methodology and bias, and limitations are transparently documented to guide appropriate application of findings. This methodology ensures that conclusions rest on a balanced synthesis of practitioner insight, device performance evidence, and regulatory context.

A concise synthesis of strategic imperatives and operational priorities that will determine which biopsy approaches gain broad adoption and clinical trust

The conclusion synthesizes the dominant themes that emerged from the analysis: that clinical imperatives, technological evolution, and operational constraints are jointly driving a shift toward more precise, less invasive, and more workflow-friendly biopsy solutions. Institutional decision-makers must weigh procedural efficacy against operational considerations such as throughput, training burden, and supply chain stability. As diagnostic pathways become increasingly integrated with molecular testing, the importance of specimen integrity and standardized handling protocols will grow.

Looking ahead, stakeholders who proactively adapt to regional regulatory requirements, engage in strategic partnerships, and invest in evidence generation will be best positioned to influence clinical practice and capture value. The interplay between innovation and practical implementation will determine which technologies achieve broad adoption and which remain niche solutions, underscoring the need for disciplined evaluation and adaptive strategies across commercial, clinical, and supply chain functions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Biopsy Market, by Product Type

  • 8.1. Core Needle Biopsy
  • 8.2. Fine Needle Aspiration
  • 8.3. Surgical Biopsy
  • 8.4. Vacuum-Assisted Biopsy

9. Cancer Biopsy Market, by Technology

  • 9.1. Imaging Guided Biopsy
  • 9.2. Manual Freehand Biopsy
  • 9.3. Robotic Assisted Biopsy

10. Cancer Biopsy Market, by Application

  • 10.1. Breast
  • 10.2. Liver
  • 10.3. Lung
  • 10.4. Prostate
  • 10.5. Thyroid

11. Cancer Biopsy Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Physicians Offices

12. Cancer Biopsy Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Cancer Biopsy Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Cancer Biopsy Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Cancer Biopsy Market

16. China Cancer Biopsy Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Argon Medical Devices, Inc.
  • 17.6. Becton, Dickinson and Company
  • 17.7. Bio-Rad Laboratories, Inc.
  • 17.8. Boston Scientific Corporation
  • 17.9. Cardinal Health, Inc.
  • 17.10. Danaher Corporation
  • 17.11. Exact Sciences Corporation
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. Guardant Health, Inc.
  • 17.14. Hologic, Inc.
  • 17.15. Illumina, Inc.
  • 17.16. Myriad Genetics, Inc.
  • 17.17. Natera, Inc.
  • 17.18. QIAGEN N.V.
  • 17.19. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER BIOPSY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER BIOPSY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOPSY MARKET SIZE, BY CORE NEEDLE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOPSY MARKET SIZE, BY FINE NEEDLE ASPIRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOPSY MARKET SIZE, BY SURGICAL BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOPSY MARKET SIZE, BY VACUUM-ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOPSY MARKET SIZE, BY IMAGING GUIDED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOPSY MARKET SIZE, BY MANUAL FREEHAND BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOPSY MARKET SIZE, BY ROBOTIC ASSISTED BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOPSY MARKET SIZE, BY BREAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOPSY MARKET SIZE, BY LIVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER BIOPSY MARKET SIZE, BY LUNG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER BIOPSY MARKET SIZE, BY PROSTATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER BIOPSY MARKET SIZE, BY THYROID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER BIOPSY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER BIOPSY MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER BIOPSY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER BIOPSY MARKET SIZE, BY PHYSICIANS OFFICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER BIOPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER BIOPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. GCC CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GCC CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. GCC CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. GCC CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. G7 CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. G7 CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. G7 CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. G7 CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. G7 CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. NATO CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. NATO CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. NATO CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. NATO CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL CANCER BIOPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. UNITED STATES CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA CANCER BIOPSY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA CANCER BIOPSY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. CHINA CANCER BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 135. CHINA CANCER BIOPSY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA CANCER BIOPSY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)